Maintaining Barriers to Entry Through High-Purity B-10, Patents, and Accumulated R&D Expertise
First written in FY2021. 1 of 2 entries say "Restated". Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022RestatedAnnual report
「The company understands that the technology for enriching B-10 to high purity (99% or more) is held domestically only by ステラケミファ株式会社, and by only 2 companies worldwide. The company has also obtained multiple patent rights relating to its formulation and plans to actively file additional peripheral patents.」
The company continues to identify high-purity B-10, formulation patents and accumulated R&D expertise as competitive advantages and barriers to entry. - FY2021First statedAnnual report
「The company understands that the technology for enriching B-10 to high purity (99% or more) is held domestically only by its parent company, ステラケミファ株式会社, and by only 2 companies worldwide. The company has also obtained multiple patent rights relating to its formulation and plans to actively file additional peripheral patents.」
The company identifies its technology for procuring high-purity B-10, formulation patents and many years of R&D as competitive advantages and barriers to entry.